首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IL27 |
| Uniprot No | Q8NEV9 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 29-243aa |
| 氨基酸序列 | FP RPPGRPQLSL QELRREFTVS LHLARKLLSE VRGQAHRFAE SHLPGVNLYL LPLGEQLPDV SLTFQAWRRL SDPERLCFIS TTLQPFHALL GGLGTQGRWT NMERMQLWAM RLDLRDLQRH LRFQVLAAGF NLPEEEEEEE EEEEEERKGL LPGALGSALQ GPAQVSWPQL LSTYRLLHSL ELVLSRAVRE LLLLSKAGHS VWPLGFPTLS PQP |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于IL-27重组蛋白的3篇文献参考，包含文献名称、作者及摘要概括：
---
1. **文献名称**: *IL-27: A Heterodimeric Cytokine with Pro- and Anti-Inflammatory Properties*
**作者**: Hunter CA, et al.
**摘要**: 该综述总结了IL-27的双重免疫调节功能，包括通过激活STAT1/STAT3信号通路抑制Th17细胞分化(抗炎作用)，以及促进Th1细胞反应(促炎作用)。文中还讨论了重组IL-27蛋白在治疗自身免疫性疾病(如多发性硬化)中的潜在应用。
2. **文献名称**: *Recombinant IL-27 Enhances Antitumor Immunity by Modulating T Cell and NK Cell Responses*
**作者**: Di Carlo E, et al.
**摘要**: 研究通过动物模型证明，重组IL-27蛋白可通过激活CD8+ T细胞和自然杀伤(NK)细胞，抑制肿瘤生长。同时发现IL-27能下调调节性T细胞(Treg)的免疫抑制功能，为癌症免疫治疗提供了新策略。
3. **文献名称**: *Structural Basis of IL-27 Receptor Signaling and Neutralization by a Pathogen-Encoded Antagonist*
**作者**: Pfanz S, et al.
**摘要**: 该研究解析了IL-27与其受体复合物的晶体结构，揭示了其结合机制。通过重组IL-27蛋白实验，发现某些病原体蛋白(如EBV的IL-27拮抗剂)可通过竞争性结合受体抑制IL-27信号，为开发IL-27靶向药物提供了结构学依据。
---
以上文献涵盖IL-27的免疫调节机制、肿瘤治疗潜力及结构生物学研究，均为领域内代表性成果。如需具体期刊信息或发表年份，建议通过PubMed或Web of Science进一步检索。
IL-27 is a heterodimeric cytokine belonging to the interleukin-12 (IL-12) family, composed of two subunits: p28 (IL-27p28) and Epstein-Barr virus-induced gene 3 (EBI3). It is primarily produced by antigen-presenting cells, such as dendritic cells and macrophages, in response to pathogen-associated molecular patterns or inflammatory stimuli. IL-27 interacts with a receptor complex comprising IL-27Rα (WSX-1) and glycoprotein 130 (gp130), activating downstream signaling pathways like JAK-STAT, which regulate immune responses.
Functionally, IL-27 exhibits dual roles in immunity. It promotes Th1 differentiation by enhancing T-bet expression and IFN-γ production while suppressing Th17 development, thereby balancing pro-inflammatory and anti-inflammatory responses. Additionally, IL-27 modulates regulatory T cell (Treg) activity and influences B cell antibody production. Its context-dependent effects make it a key player in infections, autoimmune diseases, and cancer. For example, IL-27 can limit immunopathology during parasitic infections but may also contribute to tumor immune evasion.
Recombinant IL-27 protein is engineered using mammalian expression systems (e.g., CHO or HEK293 cells) to ensure proper post-translational modifications and bioactivity. It is purified via affinity chromatography and validated through functional assays, such as lymphocyte proliferation tests. Research applications include studying IL-27's role in inflammatory disorders (e.g., multiple sclerosis, colitis), cancer immunotherapy, and infectious diseases. Preclinical studies suggest therapeutic potential in modulating immune overactivation or enhancing pathogen clearance. However, its pleiotropic effects necessitate careful evaluation in clinical settings. Current trials focus on IL-27 as a biomarker or therapeutic target, highlighting its growing relevance in immunology and translational medicine.
×
